Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KROS
KEROS THERAPEUTICS, INC.
NASDAQ
$11.03
▼ DOWN 1.78% (-0.20)

KEY STATISTICS

Market Cap$352.94 M
52w High$22.55
52w Low$9.69
Dividend Yield—
Frequency—
P/E-2.98
Volume328.29K
Shares Out.32.00M

COMPANY

LEADERSHIP

Jasbir S. Seehra
CHIEF EXECUTIVE
Jasbir S. Seehra

COMPENSATION 2026

Salary$700,000
Stock Awards$1,426,280
Incentive Plan Pay$398,125
All Other Comp.$15,799
Total$2,540,204

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 8, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
92

PRICE TARGET

Target High$23.00
Target Low$18.00
Target Median$20.00
Target Consensus$20.33

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$14.76M
NOV
4
WED

PRICE

$11.03 ▼ DOWN 1.78% (−$0.20)
$10.60$10.80$11.00$11.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM11.03

About Keros Therapeutics, Inc.

https://www.kerostx.com ↗

Keros Therapeutics is a clinical-stage biopharma developing novel treatments for hematological and musculoskeletal disorders, with lead candidates KER-050, KER-047, and KER-012 targeting conditions like anemia, cytopenias, osteoporosis, and pulmon...

INDUSTRY

Biotechnology

A PRODUCT KEROS THERAPEUTICS, INC. IS KNOWN FOR

Elritercept (KER-050)
Elritercept (KER-050)

Elritercept, Keros Therapeutics' leading clinical-stage candidate, is developed to treat cytopenias like anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis.

COMPETITORS

COMPETITOR
BMY COMPARE
GERN COMPARE
INCY COMPARE
IRON COMPARE
MRK COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q3-2025Q4-2025Q1-2026
Service Other$18.17M $4.26M ▼$385K ▼$367K ▼
License— $10M $0 ▼—

ETFS HOLDING THIS STOCK

ETFS HOLDING
84
LISTED HERE
17
RANKED BY POSITION SIZE
VTI
0.00% · 595.3K
XSU.TO
0.01% · 468.7K
BSVO
0.05% · 115.5K
SCHA
0.00% · 92.2K
DFMC
0.01% · 58.1K
PRFZ
0.02% · 55.9K
ZPRR.DE
0.01% · 55.2K
FSCC
0.10% · 32.4K
EES
0.05% · 29.8K
AVSC
0.01% · 28.0K
GSSC
0.02% · 22.3K
XRS2.DE
0.01% · 16.9K
RSSL
0.01% · 8.8K
ETLZ.DE
0.03% · 6.5K
URTY
0.00% · 750
PQ
PQSG
0.13% · 425
RESM
0.01% · 35

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.24%
HOLDERS
223
TOP 12 OF 223 · RANKED BY POSITION SIZE
Adar1 Capital Management, LLC
5.4M sh · $85.26M
Vanguard Group Inc
2.7M sh · $43.01M
Blackrock, Inc.
2.7M sh · $42.99M
Madison Avenue Partners, LP
2.7M sh · $42.84M
Blackrock Inc.
2.5M sh · $114.86M
Western Standard LLC
2.2M sh · $34.64M
Tang Capital Management LLC
1.4M sh · $22.45M
Nantahala Capital Management, LLC
1.4M sh · $15.02M
D. E. Shaw & Co., Inc.
1.3M sh · $21.06M
Goldman Sachs Group Inc
1.3M sh · $20.97M
State Street Corp
1.3M sh · $20.61M
Orbimed Advisors LLC
1.0M sh · $16.12M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Lerner Lorena Raquel
Sale · 3.6K shares
2026-08-18
★
OFFICER: CHIEF LEGAL OFFICER
Cho Esther
Sale · 4.5K shares
2026-08-18
★
DIRECTOR
Newton Charles W.
Sale · 551 shares
2026-08-18
★
OFFICER: CORP. CONTROLLER & VP, FINANCE
Tanini Annita
Sale · 1.2K shares
2026-08-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
NEUTRAL 2
OVERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
Leerink Partners OUTPERFORM Wells Fargo OVERWEIGHT B of A Securities NEUTRAL Oppenheimer OUTPERFORM Wedbush NEUTRAL

SECTORS PEERS

PEERPRICE
ABSI$8.71COMPARE
MLTX$14.99COMPARE
CRVS$14.16COMPARE
OLMA$10.27COMPARE
RIGL$46.48COMPARE
CTMX$3.21COMPARE
VSTM$7.22COMPARE
RGNX$9.66COMPARE